Orchestra BioMed Holdings Inc. has announced that its AVIM therapy has been granted Breakthrough Device Designation by the FDA. This designation is based on the significant unmet need among patients and the innovative potential of the AVIM therapy, as demonstrated by clinical results to date. The designation aims to streamline the regulatory process, providing potential pathways for securing higher reimbursement for AVIM-enabled devices in the future. This regulatory milestone supports Orchestra BioMed's goal of expanding beyond its current focus on pacemaker patients to address a broader population of high-risk hypertensive individuals. The FDA's designation is a testament to the therapy's promise and could accelerate its reach to millions of patients worldwide.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。